Miniatura

Fitxers

674076.pdf (221.46 KB)

Tipus de document

Article

Versió

Versió acceptada

Data de publicació

2018-03

Tots els drets reservats

Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/120231

First-line treatment in lymphomatoid papulosis: a retrospective multicentre study

Títol de la revista

Autors

Director/Tutor

ISSN de la revista

Títol del volum

Recurs relacionat

https://doi.org/10.1111/ced.13256

Resum

Background: Data regarding response to treatment in lymphomatoid papulosis (LyP) are scarce. Aim: To assess the daily clinical practice approach to LyP and the response to first-line treatments. Methods: This was a retrospective study enrolling 252 patients with LyP. Results: Topical steroids, methotrexate and phototherapy were the most common first-line treatments, prescribed for 35%, 20% and 14% of the patients, respectively. Complete response (CR) was achieved in 48% of treated patients. Eczematous lesions significantly increased relative risk (RR) of not achieving CR (RR = 1.76; 95% CI 1.16-2.11). Overall median time to CR was 10 months (95% CI 6-13 months), and 78% of complete responders showed cutaneous relapse; both results were similar for all treatment groups (P > 0.05). Overall estimated median disease-free survival (DFS) was 11 months (95% CI 9-13 months) but DFS for patients treated with phototherapy was 23 months (95% CI 10-36 months; P < 0.03). Having the Type A LyP variant (RR = 2.04; 95% CI 0.96-4.30) and receiving a first-line treatment other than phototherapy (RR = 5.33; 95% CI 0.84-33.89) were significantly associated with cutaneous early relapse. Of the 252 patients, 31 (13%) had associated mycosis fungoides unrelated to therapeutic approach, type of LyP or T-cell receptor clonality. Conclusions: Current epidemiological, clinical and pathological data support previous results. Topical steroids, phototherapy and methotrexate are the most frequently prescribed first-line treatments. Although CR and cutaneous relapse rates do not differ between them, phototherapy achieves a longer DFS. Presence of Type A LyP and use of topical steroid or methotrexate were associated with an increased risk of early relapse.

Matèries

Limfomes, Malalties de la pell, Fototeràpia

Matèries (anglès)

Lymphomas, Skin diseases, Phototherapy

Citació

Col·leccions

Articles publicats en revistes (Ciències Clíniques)
Articles publicats en revistes (IDIBAPS: Institut d'investigacions Biomèdiques August Pi i Sunyer)
Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))
Articles publicats en revistes (Medicina)

Citació

FERNÁNDEZ DE MISA, Ricardo, HERNÁNDEZ MACHÍN, B., SERVITJE BEDATE, Octavio, VALENTÍ MEDINA, Francesc, MAROÑAS JIMÉNEZ, L., ORTIZ ROMERO, Pablo luis, SÁNCHEZ SCHMIDT, Júlia, PUJOL, Ramon m., GALLARDO, F. (fernando), PAU CHARLES, I., GARCIA-MURET, Maria p., PÉREZ GALA, S., ROMÁN, Concepción, CAÑUETO, J., BLANCH RIUS, L., IZU, Rosa, ORTIZ BRUGUÉS, Ariadna, MARTÍ, Rosa m., BLANES, M., MORILLO, Mercedes, SÁNCHEZ, P., PEÑATE, Yerai, BASTIDA, J., PÉREZ GIL, Amalia, LOPEZ LERMA, Ingrid, MUNIESA MONTSERRAT, Cristina, ESTRACH PANELLA, Ma. teresa (maría teresa). First-line treatment in lymphomatoid papulosis: a retrospective multicentre study. _Clinical and Experimental Dermatology_. 2018. Vol. 43, núm. 2, pàgs. 137-143. [consulta: 25 de febrer de 2026]. ISSN: 0307-6938. [Disponible a: https://hdl.handle.net/2445/120231]

Exportar metadades

JSON - METS

Compartir registre